The global cancer biomarkers market has accounted to USD 9.7 billion in 2015, growing at a CAGR of 12.2% from 2016 to 2022, and is expected to reach USD 21.8 billion by 2022.
Global Cancer Biomarkers Market, By Tumor (Breast, Lung, Prostate), By Type (Protein Biomarker, Genetic Biomarkers), By Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay), By Application (Diagnostic, Drug Discovery, Prognostic), By Geography (North America, Europe, Asia-Pacific, South America, Rest of the World) – Trends and Forecast to 2022
The market is segmented based on tumor, type, profiling technology, application, and geography.
· Protein Biomarker
· Genetic Biomarkers
· Drug Discovery
Based on geographical segmentation the cancer biomarkers market is segmented into 5 regions such as North America, Europe, Asia-Pacific, South America and rest of the world. The report of this market shares covers major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, and South Africa.
Global Radiotherapy Market, By Therapy (Beam Radiotherapy (IGRT, IMRT, VMAT, Tomotherapy, 3D CRT, Proton Beam, Stereotactic), Brachytherapy (LDR, HDR), Systemic Radiotherapy), By Product Type (Cyberknife, Gammaknife, Linac, Proton Beam, Systemic Radiotherapy, Seeds, Afterloaders), By Indication (Prostate & Breast Cancer)), By Geography (North America, Europe, Asia Pacific, South America, Rest of the World) – Industry Trends and Forecast to 2024
Office Number-317, Amanora Chambers,
Magarpatta Road, Hadapsar,